Evidence map›Paper›PMID 35102475›Full record

ReviewMolecular biology reports2022

Evaluating the effects of sodium glucose co-transporter -2 inhibitors from a renin-angiotensin-aldosterone system perspective in patients infected with COVID-19: contextualizing findings from the dapagliflozin in respiratory failure in patients with COVID-19 study.

Diala Alhaj Moustafa, Zainab Imran, Roua Ismail, Menatallah Rayan, Alain-Pierre Gadeau, Hussein Eldassouki, Nabeel Abdulrahman, Fatima Mraiche

Open access · bronzeAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Molecular biology reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.8field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 3 countries.

Diala Alhaj MoustafaDepartment of Pharmaceutical Sciences, College of Pharmacy, QU Health, Qatar University, P.O. Box 2713, Doha, Qatar.
Zainab ImranDepartment of Pharmaceutical Sciences, College of Pharmacy, QU Health, Qatar University, P.O. Box 2713, Doha, Qatar.
Roua IsmailDepartment of Pharmaceutical Sciences, College of Pharmacy, QU Health, Qatar University, P.O. Box 2713, Doha, Qatar.
Menatallah RayanDepartment of Pharmaceutical Sciences, College of Pharmacy, QU Health, Qatar University, P.O. Box 2713, Doha, Qatar.
Alain-Pierre GadeauBiology of Cardiovascular Disease, INSERM, University of Bordeaux, U1034 Pessac, Bordeaux, France.
Hussein EldassoukiCollege of Kinesiology, University of Saskatchewan, Saskatoon, SK, Canada.
Nabeel AbdulrahmanDepartment of Pharmaceutical Sciences, College of Pharmacy, QU Health, Qatar University, P.O. Box 2713, Doha, Qatar.
Fatima MraicheDepartment of Pharmaceutical Sciences, College of Pharmacy, QU Health, Qatar University, P.O. Box 2713, Doha, Qatar. Fatima.Mraiche@qu.edu.qa.ORCID http://orcid.org/0000-0001-6188-1145
Qatar University · QAHamad Medical Corporation · QAUniversité de Bordeaux · FRUniversity of Saskatchewan · CA

Funding

Qatar University QUST-2-CPH-2020-16
6 · The paper itself

Abstract

Numerous studies demonstrate parallels between CVD, type 2 diabetes mellitus (T2DM) and COVID-19 pathology, which accentuate pre-existing complications in patients infected with COVID-19 and potentially exacerbate the infection course. Antidiabetic drugs such as sodium-glucose transporter-2 (SGLT-2) inhibitors have garnered substantial attention recently due to their efficacy in reducing the severity of cardiorenal disease. The effect of SGLT-2 inhibitors in patients with COVID-19 remains unclear particularly since SGLT-2 inhibitors contribute to altering the RAAS cascade activity, which includes ACE-2, the major cell entry receptor for SARS-CoV2. A study, DARE-19, was carried out to unveil the effects of SGLT-2 inhibitor treatment on comorbid disease complications and concomitant COVID-19 outcomes and demonstrated no statistical significance. However, the need for further studies is essential to provide conclusive clinical findings.

Indexed as

SARS-CoV-2Angiotensin-Converting Enzyme 2Benzhydryl CompoundsClinical Trials, Phase III as TopicCOVID-19Double-Blind MethodDrug RepositioningGlucosidesHeart DiseasesHumansKidney DiseasesMitochondriaMulticenter Studies as TopicOxidative StressRandomized Controlled Trials as TopicReceptors, VirusACE2 protein, humanAngiotensin-Converting Enzyme 2Benzhydryl CompoundsdapagliflozinGlucosidesReceptors, VirusSLC5A2 protein, humanSodium-Glucose Transporter 2Sodium-Glucose Transporter 2 InhibitorsACE-2COVID-19DapagliflozinDARE-19Renin angiotensin aldosterone systemSGLT-2

Identifiers

PMID35102475
PMCPMC8803405
OpenAlexW4210312677

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.